Analysis of the efficacy of lenalidomide in patients with intermediate‑1 risk myelodysplastic syndrome 
without 5q deletion

Yang,Yan; Gao,Sujun; Fan,Hongqiong; Lin,Hai; Li,Wei; Wang,Juan

doi:10.3892/etm.2013.1218

Analysis of the efficacy of lenalidomide in patients with intermediate‑1 risk myelodysplastic syndrome without 5q deletion

Authors:
- Yan Yang
- Sujun Gao
- Hongqiong Fan
- Hai Lin
- Wei Li
- Juan Wang
View Affiliations

Affiliations: Department of Haematology and Oncology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Oncology, People's Hospital of Jilin Province, Changchun, Jilin 130021, P.R. China
Published online on: July 11, 2013 https://doi.org/10.3892/etm.2013.1218
Pages: 803-807

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to evaluate the efficacy and adverse effects of lenalidomide in the treatment of intermediate‑1 risk non‑5q deletion [non‑del (5q)] myelodysplastic syndrome (MDS). A total of 30 patients with MDS were classified through G‑banding chromosome karyotype analysis and fluorescence in situ hybridization (FISH). According to the International Prognostic Scoring System scores, among the 30 patients, 23 and seven cases had scores of 0.5 and 1.0, respectively. Lenalidomide (Revlimid®), 10 mg/day) was administered for 21 days every 28 days. All 30 cases were treated with lenalidomide for at least three cycles, including 20 cases with four cycles. The patients did not require erythropoietin, cyclosporine or iron chelation treatments. Statistical analysis was performed using SPSS statistical software version 13.0, and comparisons among groups were conducted using a t‑test. The efficacy of lenalidomide was demonstrated in patients with intermediate‑1 risk non‑del (5q) MDS. Peripheral blood cell counts were improved following treatment, and absolute neutrophil, haemoglobin and platelet counts increased following 2‑4 cycles of treatment. All patients became stable having undergone three cycles of treatment; however, 17 patients with chromosomal abnormalities had no cytogenetic response to the treatment, as confirmed through the FISH test. Patients with intermediate‑1 risk non‑del (5q) MDS treated with lenalidomide did not achieve complete haematological remission, although they demonstrated haematological improvement.

View Figures

View References

1	Haase D, Germing U, Schanz J, et al: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 110:4385–4395. 2007. View Article : Google Scholar : PubMed/NCBI
2	Nimer SD: Myelodysplastic syndromes. Blood. 111:4841–4851. 2008. View Article : Google Scholar : PubMed/NCBI
3	Ebert BL, Galili N, Tamayo P, et al: An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 5:e352008. View Article : Google Scholar : PubMed/NCBI
4	Adès L, Boehrer S, Prebet T, et al: Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 113:3947–3952. 2009.
5	Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O’Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE and Westervelt P; National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 9:30–56. 2011.PubMed/NCBI
6	Haslett PA, Corral LG, Albert M and Kaplan G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 187:1885–1892. 1998.PubMed/NCBI
7	Davies FE, Raje N, Hideshima T, et al: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 98:210–216. 2001. View Article : Google Scholar : PubMed/NCBI
8	Chang DH, Liu N, Klimek V, et al: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 108:618–621. 2006. View Article : Google Scholar : PubMed/NCBI
9	List A, Kurtin S, Roe DJ, et al: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 352:549–557. 2005. View Article : Google Scholar : PubMed/NCBI
10	List A, Dewald G, Bennett J, et al; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 355:1456–1465. 2006. View Article : Google Scholar : PubMed/NCBI
11	List AF: Lenalidomide - the phoenix rises. N Engl J Med. 357:2183–2186. 2007. View Article : Google Scholar : PubMed/NCBI
12	Raza A, Reeves JA, Feldman EJ, et al: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 111:86–93. 2008. View Article : Google Scholar : PubMed/NCBI
13	Sekeres MA, Maciejewski JP, Giagounidis AA, et al: Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 26:5943–5949. 2008. View Article : Google Scholar : PubMed/NCBI
14	Revicki DA, Brandenburg NA, Muus P, Yu R, Knight R and Fenaux P: Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: Results from a randomized clinical trial. Leuk Res. 37:259–265. 2013. View Article : Google Scholar
15	Komrokji RS and List AF: Role of lenalidomide in the treatment of myelodysplastic syndromes. Semi Oncol. 38:648–657. 2011. View Article : Google Scholar : PubMed/NCBI
16	Giagounidis AA: Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes. Semin Hematol. 49:312–322. 2012. View Article : Google Scholar : PubMed/NCBI
17	Sugimoto Y, Sekeres MA, Makishima H, et al: Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol. 5:42012.PubMed/NCBI
18	Sibon D, Cannas G, Baracco F, et al; Groupe Francophone des Myélodysplasies. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Br J Haematol. 156:619–625. 2012. View Article : Google Scholar : PubMed/NCBI
19	Fenaux P, Giagounidis A, Selleslag DL, et al: RBC transfusion independence and safety profile of lenalidomide 5 or 10 mg in Pts with low-or Int-1-risk MDS with Del5q: Results from a randomized phase III trial (MDS-004). Blood (ASH Annual Meeting abstracts). 114:9442009.
20	Yang X, Brandenburg NA, Freeman J, et al: Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. Clin Drug Investig. 29:161–171. 2009. View Article : Google Scholar